Lindenwold Advisors Has $1.33 Million Stock Position in Merck & Co., Inc. (NYSE:MRK)

Lindenwold Advisors lowered its stake in Merck & Co., Inc. (NYSE:MRKGet Rating) by 3.4% during the first quarter, HoldingsChannel.com reports. The firm owned 16,217 shares of the company’s stock after selling 567 shares during the period. Lindenwold Advisors’ holdings in Merck & Co., Inc. were worth $1,331,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Landmark Wealth Management LLC bought a new position in Merck & Co., Inc. during the 1st quarter worth about $25,000. Joseph P. Lucia & Associates LLC bought a new position in Merck & Co., Inc. during the 1st quarter worth about $25,000. Financial Avengers Inc. grew its holdings in shares of Merck & Co., Inc. by 115.8% in the 4th quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock valued at $25,000 after acquiring an additional 176 shares in the last quarter. Front Row Advisors LLC grew its holdings in shares of Merck & Co., Inc. by 89.4% in the 4th quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock valued at $26,000 after acquiring an additional 160 shares in the last quarter. Finally, Okabena Investment Services Inc. bought a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $27,000. Institutional investors and hedge funds own 72.88% of the company’s stock.

Merck & Co., Inc. Trading Up 0.4 %

MRK stock traded up $0.37 during midday trading on Friday, hitting $87.19. The stock had a trading volume of 361,214 shares, compared to its average volume of 8,495,317. The firm has a market cap of $220.49 billion, a P/E ratio of 13.30, a price-to-earnings-growth ratio of 1.18 and a beta of 0.32. The company has a current ratio of 1.40, a quick ratio of 1.14 and a debt-to-equity ratio of 0.75. Merck & Co., Inc. has a 1-year low of $70.89 and a 1-year high of $95.72. The business has a fifty day moving average price of $90.38 and a two-hundred day moving average price of $85.34.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its quarterly earnings data on Thursday, July 28th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.69 by $0.18. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 50.02%. The firm had revenue of $14.59 billion for the quarter, compared to analyst estimates of $13.85 billion. During the same quarter in the prior year, the business earned $1.31 earnings per share. The business’s quarterly revenue was up 28.0% compared to the same quarter last year. On average, sell-side analysts predict that Merck & Co., Inc. will post 7.31 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be issued a $0.69 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.17%. Merck & Co., Inc.’s dividend payout ratio is presently 42.27%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on MRK shares. Cowen raised their price objective on Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a report on Monday, June 27th. Barclays raised their price objective on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a report on Tuesday, April 12th. SVB Leerink reiterated an “outperform” rating and set a $102.00 price target on shares of Merck & Co., Inc. in a report on Monday, June 6th. Atlantic Securities raised their price objective on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 13th. Finally, Cowen raised their price objective on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the stock a “market perform” rating in a research report on Monday, June 27th. Eight equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and a consensus price target of $97.44.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.